mitoxantrone has been researched along with Depressive Disorder, Treatment-Resistant in 1 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Depressive Disorder, Treatment-Resistant: Failure to respond to two or more trials of antidepressant monotherapy or failure to respond to four or more trials of different antidepressant therapies. (Campbell's Psychiatric Dictionary, 9th ed.)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duprat, R | 1 |
| Desmyter, S | 1 |
| Rudi, de R | 1 |
| van Heeringen, K | 1 |
| Van den Abbeele, D | 1 |
| Tandt, H | 1 |
| Bakic, J | 1 |
| Pourtois, G | 1 |
| Dedoncker, J | 1 |
| Vervaet, M | 1 |
| Van Autreve, S | 1 |
| Lemmens, GM | 1 |
| Baeken, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Establishing Functional Biomarkers for Spaced Theta-Burst Stimulation[NCT03687892] | 37 participants (Actual) | Interventional | 2019-04-01 | Terminated (stopped due to Change in study personnel.) | |||
| Accelerated Theta Burst in Chronic Pain: A Biomarker Study[NCT03984201] | 60 participants (Anticipated) | Interventional | 2023-06-30 | Not yet recruiting | |||
| Using Multiple Brain-based Biomarkers to Validate and Predict Response to Theta Burst Stimulation as a New Treatment for Major Depressive Disorder[NCT03626181] | 30 participants (Anticipated) | Interventional | 2018-07-06 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for mitoxantrone and Depressive Disorder, Treatment-Resistant
| Article | Year |
|---|---|
Accelerated intermittent theta burst stimulation treatment in medication-resistant major depression: A fast road to remission?
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Cytarabine; | 2016 |
Accelerated intermittent theta burst stimulation treatment in medication-resistant major depression: A fast road to remission?
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Cytarabine; | 2016 |
Accelerated intermittent theta burst stimulation treatment in medication-resistant major depression: A fast road to remission?
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Cytarabine; | 2016 |
Accelerated intermittent theta burst stimulation treatment in medication-resistant major depression: A fast road to remission?
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Cytarabine; | 2016 |
Accelerated intermittent theta burst stimulation treatment in medication-resistant major depression: A fast road to remission?
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Cytarabine; | 2016 |
Accelerated intermittent theta burst stimulation treatment in medication-resistant major depression: A fast road to remission?
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Cytarabine; | 2016 |
Accelerated intermittent theta burst stimulation treatment in medication-resistant major depression: A fast road to remission?
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Cytarabine; | 2016 |
Accelerated intermittent theta burst stimulation treatment in medication-resistant major depression: A fast road to remission?
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Cytarabine; | 2016 |
Accelerated intermittent theta burst stimulation treatment in medication-resistant major depression: A fast road to remission?
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Cytarabine; | 2016 |